dalutrafusp alfa   Click here for help

GtoPdb Ligand ID: 11776

Synonyms: AGEN-1423 | AGEN1423 | GS-1423
Compound class: Antibody
Comment: Dalutrafusp alfa is a bispecific antibody-fusion protein that was designed as a checkpoint modulator for immuno-oncology. It was invented by Agenus (as AGEN-1423), and has been licensed to Gilead for clinical development (as GS-1423). The antibody portion of dalutrafusp targets the adenosine degrading enzyme ecto-5'-nucleotidase (NT5E/CD73; produces an immunosuppressive effect in the tumour micoenvironment), and this is fused via a peptidyl linker to the extracellular domain of transforming growth factor beta receptor 2 (TGFBR2) which acts as a molecular trap for both TGFβ1 and TGFβ3. NT5E and TGFβ are two significant resistance pathways that allow tumours to escape immune surveillance.
In the absence of a peer reviewed disclosure, analysis of patent documents suggests that dalutrafusp alfa may be closely related to the anti-CD73-TGF trap fusion protein BA037 that is claimed in Agenus' patent WO2019173692A2 [1]. The CDRs in the sequences of the anti-NT5E/CD73 mAb region from the dalutrafusp alfa INN document match SEQ IDs presented in the patent.
Click here for help
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
11814 dalutrafusp alfa
Synonyms Click here for help
AGEN-1423 | AGEN1423 | GS-1423
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1225
Other databases
GtoPdb PubChem SID 458923811
Search PubMed clinical trials dalutrafusp alfa
Search PubMed titles dalutrafusp alfa
Search PubMed titles/abstracts dalutrafusp alfa